Beacon Pointe Advisors LLC Has $220,000 Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Beacon Pointe Advisors LLC cut its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 32.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 935 shares of the biopharmaceutical company’s stock after selling 440 shares during the period. Beacon Pointe Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $220,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Artia Global Partners LP raised its position in Alnylam Pharmaceuticals by 61.1% during the 4th quarter. Artia Global Partners LP now owns 56,400 shares of the biopharmaceutical company’s stock worth $13,271,000 after purchasing an additional 21,400 shares during the last quarter. Aquatic Capital Management LLC raised its holdings in Alnylam Pharmaceuticals by 98.7% during the 4th quarter. Aquatic Capital Management LLC now owns 40,552 shares of the biopharmaceutical company’s stock worth $9,542,000 after purchasing an additional 20,143 shares during the last quarter. Susquehanna Fundamental Investments LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $13,315,000. Two Sigma Securities LLC increased its position in shares of Alnylam Pharmaceuticals by 272.3% during the fourth quarter. Two Sigma Securities LLC now owns 1,117 shares of the biopharmaceutical company’s stock worth $263,000 after buying an additional 817 shares during the period. Finally, Kovitz Investment Group Partners LLC lifted its holdings in Alnylam Pharmaceuticals by 8.3% in the fourth quarter. Kovitz Investment Group Partners LLC now owns 2,633 shares of the biopharmaceutical company’s stock valued at $620,000 after buying an additional 202 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on ALNY shares. Chardan Capital lifted their price objective on Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the stock a “buy” rating in a research report on Friday. UBS Group lifted their target price on Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the stock a “buy” rating in a report on Friday. HC Wainwright restated a “buy” rating and set a $500.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 2nd. Stifel Nicolaus lifted their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a “buy” rating in a research note on Monday, March 31st. Finally, Citigroup raised their price target on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a “buy” rating in a report on Friday, March 21st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have assigned a buy rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $319.17.

Insider Buying and Selling

In other news, EVP Kevin Joseph Fitzgerald sold 663 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.21, for a total value of $169,204.23. Following the sale, the executive vice president now owns 14,321 shares of the company’s stock, valued at $3,654,862.41. The trade was a 4.42 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Yvonne Greenstreet sold 1,213 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $309,521.21. Following the completion of the transaction, the chief executive officer now directly owns 81,526 shares of the company’s stock, valued at approximately $20,802,989.42. This trade represents a 1.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 7,392 shares of company stock valued at $1,875,627. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Stock Up 5.5 %

ALNY opened at $273.55 on Tuesday. The company’s 50-day moving average price is $248.81 and its two-hundred day moving average price is $254.55. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals, Inc. has a twelve month low of $144.73 and a twelve month high of $304.39. The stock has a market cap of $35.58 billion, a price-to-earnings ratio of -126.06 and a beta of 0.17.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The business had revenue of $594.19 million during the quarter, compared to analyst estimates of $584.32 million. The company’s revenue for the quarter was up 20.2% compared to the same quarter last year. During the same period last year, the business posted ($0.16) earnings per share. As a group, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.